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Thesis Abstract
GLAST, GLT-1, EAACl, and EAAT4 are high-affinity, sodium-dependent glutamate 
transporters identified in the mammalian central nervous system (CNS). In this study, the 
expression patterns of these transporter subtypes were characterized in two types of 
primary cell cultures: cerebellar granule neurons (CGN) and mixed CGN/glial cultures. 
Both culture types have been used extensively in studies of glutamate-mediated 
excitotoxicity. Cells were isolated from 7-day-old rat cerebella and grown for 10 days. 
Obtaining > 90% pure CGN cultures was achieved by adding cytosine arabinoside to halt 
the proliferation of glial cells, whereas the mixed CGN/glial cell cultures were obtained 
by permitting glial cell proliferation. Subtype-specific anti-peptide antibodies were used 
to identify the glutamate transporters. Antibodies against neuronal cell markers (anti­
neuronal nuclei (NeuN) and anti-neurofilament (NF)) and against an astrocyte marker 
(anti-glial fibrillary acidic protein (GFAP)), were used to determine cell type specific 
expression of the transporters. The results indicate that both CGN and mixed CGN/glial 
cell cultures contain cells that are immunopositive for the glutamate transporters GLAST, 
GLT-1, EAACl, and EAAT4. While GLAST and GLT-1 are generally designated as 
“glial glutamate transporters”, we report here that GLAST and GLT-1 immunostaining is 
predominantly found on cells that are immunopositive for the neuronal cell markers, NF 
and NeuN. The previously reported “neuronal glutamate transporter”, EAACl, localizes 
to NF and NeuN positive cells only in these culture systems. However, the previously 
described “neuronal glutamate transporter”, EAAT4, localizes predominantly to GFAP 
positive cells. These findings demonstrate that expression patterns in vitro do not 
necessarily mimic previously reported in vivo glutamate transporter expression patterns. 
Additionally, in the mixed CGN/glial cell cultures, we demonstrate that both GLAST and 
EAAT4 appear to be expressed by a greater number of GFAP positive astrocytes than in 
the CGN cultures. GLT-1 and EAACl expression appears consistent between both 
culture systems. These findings represent an important foundation for future studies 
involving glutamate transporters, particularly as related to regulation of expression, 
functional studies, developmental expression, and glutamate-mediated excitotoxicity.
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INTRODUCTION
L-G lutam ate
L-Glutamate (L-GLU) has attracted considerable attention in recent years because 
of its role as both the primary excitatory amino acid (EAA) neurotransmitter in the 
mammalian central nervous system (CNS) and as a potent neurotoxin. Beginning with 
the demonstration of the convulsive properties of L-GLU and the direct activation of 
CNS neurons by this EAA, considerable effort has been directed toward establishing the 
role of L-GLU in fast excitatory neurotransmission (Curtis et al., 1959; Takahashi et al., 
1997; Bridges, 2001). Numerous techniques including immunocytochemistry, 
pharmacology, and electrophysiology collectively demonstrate that L-GLU exhibits the 
classic characteristics of a neurotransmitter. Thus, L-GLU is sequestered in synaptic 
vesicles, released into the synaptic cleft in a C a^  dependent manner, activates receptors 
for signal propagation, and is rapidly transported into neurons and neighboring glial cells 
for the purposes of signal termination and transmitter recycling (Kanai et al., 1994a). In 
addition to its role in standard fast synaptic communication, L-glutamate-mediated 
neurotransmission plays a role in higher order signal processing (e.g., learning, memory, 
developmental plasticity), as well as in neuropathology (e.g., Alzheimer’s disease, stroke) 
(Choi, 1988; Lipton and Rosenberg, 1994; Billups et al., 1998).
The diversity of actions o f L-GLU is to a great extent attributable to a 
sophisticated receptor system. Multiple receptor classes for L-GLU, have been identified 
and cloned, including both ionotropic and metabotropic receptor families. lonotropic 
(ion channel-coupled) L-GLU receptors are named after selective agonists and include: 
N-methyl-D-aspartate (NMDA), kainic acid (KA), and a-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors. These receptors are coupled to both 
voltage-dependent and voltage-independent ion channels that gate currents carried by 
Na^, K^, and sometimes Ca"^. Unlike the ionotropic KA and AMPA receptors, which are 
principally thought to mediate fast excitatory signaling, the ionotropic NMDA receptor 
and the metabotropic receptors are involved in the higher order processing required in 
development, plasticity, learning, and memory (Monaghan et al., 1989). The 
metabotropic L-GLU receptors (mOluRs) are coupled by guanine nucleotide binding 
proteins (G proteins) to intracellular second messenger systems. To date, the mGluR 
family comprises eight receptor subtypes that are divided into three groups based on 
coupling to second messengers, sequence similarity, and ligand selectivity (Conn and Pin,
1997). G roup I includes m G luRl and mGluR5, which are coupled to 
polyphosphoinositide (PPI) hydrolysis. MGluRs from groups II (mGluR2 and mGluR3) 
and III (mGluR4, mGluR6, mGluRV, and mGluRS) are negatively coupled to adenylate 
cyclase activity. In addition, a mGluR receptor coupled to phospholipase D has been 
identified in the hippocampus (Monaghan et al., 1989).
Although L-GLU receptors typically participate in normal physiological 
signaling, overactivation of some receptor subtypes can mediate neuronal degeneration. 
The ability of L-GLU to damage neurons is specifically referred to as excitotoxicity, a 
term coined by J.W. Olney (Olney, 1982). L-Glutamate receptor overactivation occurs 
when an agonist, such as glutamate or kainate, is present at the synaptic cleft in elevated 
concentrations. L-Glutamate receptor-mediated neurotoxicity is comprised of at least 
two components: osmotic-mediated damage and Ca^^-mediated damage (Kiedrowski,
1999). Osmotic-mediated neurotoxicity occurs when excessive levels of L-GLU produce
a large influx of Na^ through ionotropic receptors followed by membrane depolarization 
and the passive influx of Cl" and H 2 O. The excessive influx of ions subsequently leads to 
membrane swelling and cell lysis (Dunlop et al., 1999). This type of neurotoxicity is 
typically acute, occurring within minutes of excitotoxic onset. Conversely, calcium- 
mediated neurotoxicity is primarily caused by overactivation of NMDA receptors by L- 
GLU and is marked by gradual cellular disintegration. In normal physiological signaling, 
activation of select ionotropic receptors causes membrane depolarization, accompanied 
by cation influx (especially Ca^^). This intracellular Ca^^ then acts as a second 
messenger that can modify numerous properties within the postsynaptic cell. Chronic 
overactivation of the NMDA receptor, however, leads to a rapid and persistent increase in 
cytoplasmic free Ca^^ (Choi, 1995). This leads to the overactivation of many Ca"^- 
regulated enzymes (e.g., pro teases, lipases, cyclooxygenases) as well as to the induction 
of a number of pathological schemes, such as free radical production (Choi, 1987; 
Castilho et al., 1998). Both osmotic- and Ca^^-mediated neuronal cell deaths have been 
reported to occur by necrosis or apoptosis, or a combination of both types of cell death 
(Dunlop et al., 1999). L-Glutamate mediated excitotoxicity involving either osmotic- 
mediated or Ca^^-mediated cell death, or both, has been implicated in acute 
neuropathologies (e.g., ischemia and spinal cord trauma), as well as chronic 
neuropathologies (Huntington’s disease, Amyotropic Lateral Sclerosis (ALS), and 
Alzheimer’s disease) (Rothstein et al., 1993; Olney et al., 1997; Roettger and Amara, 
1999; Meldrum, 2000; Rowland, 2000).
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L-G lutam ate Transporters (Excitatory Am ino Acid Transporters, EAATs)
The potential for L-GLU to participate in either normal cellular signaling or 
pathology suggests that extracellular L-GLU concentrations must be carefully controlled 
(Olney et al., 1986; Choi et al., 1987; Headley, 1990). L-Glutamate transporters are 
believed to be essential to this regulation. While L-GLU can act as a substrate of 
numerous cellular uptake systems, the specific L-GLU transporters that are thought to 
play a primary role in CNS excitatory neurotransmission are referred to as the high- 
affinity, sodium-dependent transporters. Efficient removal o f L-GLU from the 
extracellular space by high-affinity, Na^-dependent, excitatory amino acid transporters 
(EAATs) is postulated to contribute to signal termination, transmitter recycling, and 
maintenance of L-GLU concentrations below those which are excitotoxic (Cotman et al., 
1995; Billups et al., 1998).
The presence of high-affinity transporter systems for L-GLU in CNS tissue was 
first described by Logan and Snyder in 1971 (Logan W.J., 1971). Initially characterized 
as both high- and low- affinity uptake components for the accumulation of radiolabelled 
amino acid into rat brain synaptosomes, it was subsequently suggested that the high- 
affinity component may represent a mechanism for the removal of synaptically released 
L-GLU, thereby inactivating L-GLU neurotransmitter activity. In contrast, the low- 
affinity uptake component, described as responsible for metabolic trafficking, did not 
appear to function in the process of neurotransmission (Dunlop et al., 1999). Subsequent 
studies have demonstrated that Na'^-dependent, high-affinity L-GLU transport occurs in a 
sodium-, potassium-, and energy dependent manner, relying on transmembrane ion
gradients from the Na /K pump (Meldrum, 2000). Research has also shown that the ion 
gradients used to drive the uptake of L-GLU are necessary to maintain high intracellular 
concentrations o f L-GLU. Under normal conditions, L-GLU concentrations in the 
extracellular space range between 0.6 pM and 10 pM, while, estimated intracellular L- 
GLU concentrations in neurons and glial cells are 5-20mM and 0.1-5mM, respectively 
(Kuhar and Zarbin, 1978). Thus, EAATs function to maintain intracellular L-GLU 
concentrations at 10,000 times the extracellular concentrations (Nicholls, 1990), a 
process which can be achieved in milliseconds (Diamond and Jahr, 1997; Grewer et al.,
2000). Consequently, loss of ion gradient control can lead to an efflux of L-GLU through 
the transporters, increased concentrations of extracellular L-GLU, and an increased 
likelihood of excitotoxic pathology (Takahashi et al., 1997; Koch et al., 1999).
Similar to the diversity of the EAA receptor system, evidence indicates high- 
affinity EAA transport is not mediated by a single transporter system. Existence of 
multiple subtypes of EAATs emerged when kinetic and pharmacological properties of 
Na-dependent L-GLU uptake were compared in different cell types or brain regions 
(Balcar et al., 1987; Kanai, 1992; Bridges et al., 1999; Fairman and Ameu-a, 1999; Koch 
et al., 1999; Brauner-Osborne et al., 2000). L-Glutamate uptake inhibitors such as 
dihydrokainic acid (DHK), L-a-aminoadipic acid (L-a-AA), and L-^ra«.s-2,4-pyrrolidine 
dicarboxylate (2,4-PDC) exhibit a variety of potencies dependent on both regional 
specificity and cell types (Bridges et al., 1991). The existence o f distinct L-GLU 
transporters was confirmed by nearly simultaneous isolation of three cDNAs from non­
human species, each encoding a distinct transporter subtype: glutamate/aspartate 
transporter (GLAST) (Storck et al., 1992), glutamate transporter-1 (GLT-1) (Pines et al..
1992), and excitatory amino acid carrier 1 (EA A Cl) (Kanai, 1992). The human 
homologues of these were subsequently cloned and named EAATl, EAAT2, and EAAT3 
(Arriza et al., 1994). Cloning of the plasma membrane glutamate transporters revealed 
that they are members o f a unique family of molecules separate from the other 
neuro transmitter transporters such as GAB A, glycine, noradrenaline, dopamine, and 5- 
hydroxytryptamine. L-Glutamate is recognized as the predominant endogenous substrate 
for these transporters, although D- and L- aspartate, as well as a number of sulfur 
containing EAA analogues, can also be translocated by these transporters (Dunlop et al., 
1999). In addition to EAATl (GLAST), EAAT2 (GLT-1), EAATS (EAACl), two more 
transporters have been cloned, EAAT4, and EAATS (Arriza et al., 1994; Rothstein et al., 
1994; Fairman, 1995; Gegelashvili and Schousboe, 1998), bringing the total to five. 
Although each EAAT subtype has a distinct pharmacology and distribution within the 
CNS, they exhibit sequence homology of 40-65% within species. When individual 
subtypes are compared across species, they demonstrate 90% homology. Both neurons 
and glia are capable of mediating high-affinity, sodium-dependent L-GLU transport 
through the expression of various EAATs (Gadea and Lopez-Colme, 2001). An essential 
step towards understanding the contribution of EAATs to L-GLU-mediated physiology 
and pathology is the elucidation of specific roles and functions of each transporter 
subtype.
Role o f EAA Ts in Synaptic Transm ission
Although the EAATs are thought to participate in signal termination, transmitter 
recycling, and maintenance of L-GLU concentrations below those, which are excitotoxic, 
the relative contribution of each transporter subtype to each of these roles has not been
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firmly established. Neurotransmitter recycling occurs by the well-described glutamate- 
glutamine cycle. L-Glutamate is released from synaptic vesicles in the presynaptic 
neuron to evoke an excitatory signal in a neighboring neuron. High-affinity, L-GLU 
transporters on surrounding astrocytes, then preferentially take up L-GLU, where it is 
rapidly converted to glutamine by the glial-specific enzyme, glutamine synthetase 
(Alvarez-Maubecin et al., 2000). Astrocytes then release glutamine and it is 
subsequently taken up by neurons and utilized for synthesis o f new L-GLU 
(Waagepetersen et al., 2000). This cycle allows for replenishment of L-GLU in neurons, 
as these cells lack an anaplerotic pathway for net synthesis of this neurotransmitter. 
Thus, transporter expression in both neurons and astrocytes is critical to normal function 
of the EAA system.
The role o f the EAAT system in maintaining L-GLU concentrations below those 
that are excitotoxic has become clearer through the utilization of transport inhibitors. Co­
administration of L-GLU with a Na^-dependent uptake inhibitor, P-threo-hydroxy 
aspartate, produces greater in vivo pathology than administration of L-GLU alone (Seal 
and Amara, 1999). These studies suggest that decreased transporter activity may increase 
extracellular L-GLU concentrations, and increase the likelihood of L-GLU-mediated 
excitotoxicity. An inverse relationship between excitotoxic damage and EAAT capacity 
is also suggested by studies showing that greater concentrations of L-GLU are required to 
produce lesions in vivo than EAA agonists that are non-transportable substrates (Seal and 
Amara, 1999). Abnormalities in L-GLU transport are thought to be associated with 
specific neuropathologies. Studies have shown that EAAT2 expression is decreased in 
the motor cortex and spinal cord of patients with the sporadic form of ALS, leading to
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elevations of L-GLU in the cerebral spinal fluid (Ye et al., 1999). Additionally, evidence 
implicates the dysregulation o f activity and/or expression o f the EAATs in the 
pathogenesis o f several acute neurological diseases, including brain ischemia, brain or 
spinal cord trauma, and epilepsy (Dunlop et al., 1999), as well as in slowly progressing 
neurodegenerative disorders such as Huntington’s chorea and Alzheimer’s disease 
(Rothstein et al., 1996; Takahashi et al., 1997; Trotti et al., 1998).
The EAATs are also thought to play an essential role in signal termination. 
Studies using electrophysiological methods and transport inhibitors demonstrate altered 
postsynaptic signaling in subsets of glutamatergic synapses (Diamond and Jahr, 2000). 
Subsequent investigations showed that the transport inhibitors, p-THA and \^-trans-2,A- 
PDC, slow AMPA receptor-mediated postsynaptic currents in climbing and parallel fiber 
synapses of cerebellar Purkinje neurons, suggesting they affect the speed of clearance of 
transmitter. However, these inhibitors showed no measurable effect in modulating 
postsynaptic response kinetics in other glutamatergic synapses in the cerebellum and 
hippocampus (Sarantis et al., 1993; Bridges et al., 1999). Thus, the development of novel 
selective inhibitors may further elucidate whether the distinct EAAT subtypes can 
influence the strength of excitatory signaling by modulating concentration and/or time 
course of L-GLU at individual synapses (Bridges et al., 1999). Additional roles for the 
EAATs in excitatory signaling have been suggested: 1) transport may limit 
desensitization of postsynaptic receptors, 2) uptake may limit the diffusion of L-GLU 
thus preventing “spill-over” and unwanted activation of L-GLU receptors, and 3) 
transport may play a role in maintaining a high specificity of synaptic transmission by
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limiting the extent o f cross talk between neighboring synapses (Rothstein et al., 1996; 
Dunlop et al., 1999).
Distribution o f L-G lutam ate Transporters
Cloning of the EAATs in the early 1990’s enabled the production of sequence- 
specific molecular probes (cDNA and oligo probes, and antipeptide antibodies) to 
elucidate the distribution o f individual transporters and corresponding mRNA 
(Gegelashvili and Schousboe, 1998). These probes have dem onstrated that 
GL AST/E A AT 1 is abundant in the CNS, as well as in peripheral tissues, such as heart, 
muscle, placenta, lung, liver, testes, and retina in several species (Furness and Lehre, 
1997; Gegelashvili and Schousboe, 1998; Seal and Amara, 1999). GLT-1/EAAT2 
mRNA localizes to the CNS of human and rodent, with low levels of expression in 
placenta. EAACl/EAAT3 mRNA is abundant in the CNS, although it has also been 
detected in kidney, heart, muscle, lung, placenta, and liver (Gegelashvili and Schousboe, 
1998). While GLAST/EAAT 1 and EAAC1/EAAT3 demonstrate significant distribution 
in peripheral tissues, GLT-1/EAAT2 is thought to be more specific to the CNS (Rothstein 
et al., 1994). The more recently cloned transporter, EAAT4 (Fairman, 1995) is found 
predominantly in the CNS with some expression observed in the placenta (Gegelashvili 
and Schousboe, 1998) while, the most recently identified transporter, EAAT5 (Arriza et 
al., 1997) localizes to the retina (Danbolt et al., 1998; Eliasof et al., 1998; Vandenberg,
1998).
Regional distribution studies within the CNS demonstrate that the cerebellum is 
specifically enriched with GLAST/EAATl, with lower expression levels in the forebrain 
and the olfactory bulb (Rothstein et al., 1994). High expression levels of GLT-1/EAAT2
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mRNA are detected in hippocampus, cerebral cortex, thalamus, and striatum, with lower 
expression observed in brain stem, spinal cord, cerebellum, and olfactory bulb (Rothstein 
et al., 1994). Localization studies of EAACl/EAAT3 demonstrate high expression levels 
in cerebral cortex, caudate-putamen, hippocampus, and olfactory bulb, with lower levels 
in spinal cord and cerebellum (Rothstein et al., 1994). High levels of EAAT4 are 
localized in the cerebellum, particularly in the Purkinje cell layer, with low levels of 
expression in other forebrain regions including hippocampus and cortex (Furuta et al., 
1997).
Considerable research has been devoted to the cellular localization of L-GLU 
transporters both in vivo and in vitro (Gegelashvili and Schousboe, 1998; Seal and 
Amara, 1999). It is now generally accepted that GLAST/EAATl is the most abundant 
transporter in the cerebellum and is expressed in both glial cells and in neurons. Initial 
cloning experiments revealed GLAST/EAATl protein expression predominantly 
localized to astrocytes (Arriza et al., 1994). However, reports have since shown that 
GLAST/EAATl mRNA and protein localizes to various neuronal cell types including 
cerebellar granule neurons, rat cochlear hair cells, and neuronal cell lines (Rothstein et 
al., 1994). GLT-1/EAAT2 primarily localizes to astrocytes, thus GLT-l/EAAT2’s 
designation as the “glial glutamate transporter”. Initial studies reported GLT-1/EAAT2 
protein exclusively in rat astrocytes (Danbolt et al., 1998) however, GLT-1/EAAT2 
mRNA has been found in vitro  in cultures o f rat astrocytes, microglia and 
oligodendrocytes. Additionally, GLT-1/EAAT2 shows some, although limited neuronal 
expression, GLT-1 mRNA had been found in a subset of hippocampal neurons (Torp et 
al., 1994). Despite EAACl/EAAT3 being commonly referred to as the “neuronal
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glutamate transporter”, EAACl/EAAT3 protein has been found in the rat C6 glioma cell 
line and several human tumors of glial origin (Kanai, 1992; Kanai et al., 1994a; Rothstein 
et al., 1994; Vandenberg, 1998). Within the CNS, BAAT4 is expressed predominantly in 
Purkinje cell layer neurons (Vandenberg, 1998). Finally, EAAT5 localizes to the retina 
with specific cellular localization yet to be determined (Arriza et al., 1994).
Studies examining the subcellular distribution of the EAATs have provided great 
insight into the functional significance of different subtypes of high affinity L-GLU 
transporters. GLAST/EAATl and GLT-1/EAAT2 proteins are situated in the plasma 
membrane o f neurons and glial cells, with highest transporter density in the thin 
processes where transporters colocalize and likely couple functionally with glutamine 
synthetase (Derouiche and Rauen, 1995; Gegelashvili and Schousboe, 1998). 
Interestingly, GLT-1/EAAT2 is not expressed uniformly in astrocyte membranes. More 
GLT-1/EAAT2 protein is present in those portions of glial cell membranes that face 
nerve terminals, axons, and dendritic spines (Takahashi et al., 1997). These findings are 
consistent with the hypothesis that glial glutamate transporter uptake functions to 
maintain L-GLU concentration below neurotoxic levels (Takahashi et al., 1997). 
Neuronal L-GLU uptake is conventionally thought to occur in presynaptic terminals, 
where it terminates the synaptic action of L-GLU and recycles the transmitter into 
synaptic vesicles for re-use (Yamada et al., 1996). However, EAAC1/EAAT3 expression 
has been found throughout the soma and dendritic tree of Purkinje cells (Rothstein et al., 
1994) and further studies have demonstrated EAACl/EAAT3 immunoreactivity in 
presynaptic boutons of GABAergic neurons (Gegelashvili and Schousboe, 1998). Tissue
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distribution, CNS distribution, cellular distribution, and developmental expression 
patterns of the L-GLU transporter subtypes are summarized in Table 1.
A differential function for GLAST/EAATl and GLT-1/EAAT2, compared to 
EAAC1/EAAT3 is suggested by experiments in which molecular biological methods 
were used to prevent transporter expression (Rothstein et ah, 1996). Deleting 
GLAST/EAATl and GLT-1/EAAT2 led to a general rise o f extracellular L-GLU 
concentrations, which induced neuronal cell death (Rothstein et ah, 1994). In contrast, 
loss of EAACl/EAAT3 was reported to not produce a rise in extracellular L-GLU 
concentrations (Gegelashvili and Schousboe, 1998). Further studies are needed to clarify 
not only the roles of these three transporters but also the roles of EAAT4 and EAATS.
Table 1. Distribution of Glutamate Transporters
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TRANSPORTER
SUBTYPE
MAMMALIAN
TISSUE
DISTRIBUTION
REGIONAL 
DISTRIBUTION 
WITHIN THE CNS
CELLULAR
DISTRIBUTION
DEVELOPMENTAL
EXPRESSION
PATTERNS
GLASTV 
EAAT F
CNS 
Skeletal Muscle 
Liver 
Lung 
Placenta
Cerebellum 
Forebrain 
Olfactory Bulb
Neurons
Astrocytes 
- Bergmann Glia
Increases during 
development^
GLT-17
EAAT2^
CNS 
Placenta 
Pineal Gland 
Retina
Cerebral Cortex 
Hippocampus 
Thalamus 
Spinal Cord 
Cerebellum
Neurons 
- limited
Astrocytes
Increases during 
development^
EAACl V 
EAAT3^
CNS
Intestine
Kidney
Liver
Heart
Placenta
Cerebellum 
Hippocampus 
Olfactory Bulb 
Spinal Cord 
Caudate Putamen
Neurons Decreases during 
development^
EAAT4^ CNS
Placenta
Cerebellum 
Hippocampus 
Cerebral Cortex
Neurons
- Granule
- Purkinje
maybe
Astrocytes
Increases during 
development^
EAAT5^ Retina ?? ??
_________
(Storck et al., 1992) 
(Arriza et al., 1994) 
(Bar-Peled et al., 1997) 
(Pines et al., 1992) 
(Kanai, 1992) 
(Fairman, 1995) 
(Eliasof et al., 1998)
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R egulation o f  Transporter Expression
Recent evidence that EAAT expression is a developmentally regulated process 
has emerged from studies utilizing mouse and rat CNS and spinal cord tissue (Sutherland 
et al., 1996; Furuta et al., 1997). Prenatally, GLAST expression predominates, with very 
low levels of GLT-1 in evidence (Bar-Peled et al., 1997). Postnatally, both GLAST and 
GLT-1 increase dramatically during periods corresponding to synaptogenesis. Similar 
changes in EAAT 1-4 expression have recently been described in human brain during 
development (Bar-Peled et al., 1997).
Primary dissociated CNS cultures remain a useful tool for the investigation of 
EAAT expression and neurotransmitter uptake and metabolism by different cell types 
during development (Reynolds and Herschkowitz, 1987). However, in vitro culture 
systems must be used with some caution. Various in vitro culture systems exhibit 
different patterns of EAAT expression from those found in vivo, indicating growth 
conditions may influence EAAT expression. For example, cultured astrocytes do not 
exhibit the same high levels of expression of the GLT-1/EAAT2 subtype, characteristic 
of adult brain (Gegelashvili et al., 1997). Manipulating astrocyte cultures has also been 
shown to alter EAAT expression patterns. Exposure to neuron-conditioned medium 
(Gegelashvili and Schousboe, 1997a), co-culture with neurons (Swanson et al., 1997), 
and exposure to dibutyryl cAMP (Schlag et al., 1998) all result in a dramatic upregulation 
of EAAT2 expression in astrocytes. Studies demonstrating changes in EAAT expression 
raise the possibility o f identifying factors, which may increase or decrease EAAT 
expression both in vivo and in vitro, providing insight into transporter abnormalities and 
alterations during disease states and also as potential therapeutic targets.
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Specific Aim s
The purpose of the present work is to obtain fundamental information about 
EAAT distribution in primary cell cultures as a tool for evaluating the roles of the 
EAATs, particularly as related to excitotoxicity. Before a clear understanding of 
transporter function can be attained, it is necessary to determine EAAT distribution 
patterns and expression levels. Therefore, this project will define the cellular distribution 
of the excitatory amino acid transporters, GLAST, GLT-1, EAACl, and EAAT4, in 
cerebellar granule neuron (CGN) cultures. Additionally, this project will examine 
changes in EAAT expression associated with the presence of glial cells. The glial cell- 
depleted population is greater than 90% homogenous, containing predominantly CGNs 
(Schousboe et al., 1985; Schousboe et al., 1989). In contrast, the glial cell-enriched 
populations (mixed neuron/glial cell cultures) are heterogeneous, containing not only 
CGNs, but also astrocytes and a few oligodendrocytes (Campbell and Shank, 1978). 
Cerebellar granule neurons were chosen for the following reasons: 1) CGNs are 
glutamatergic neurons (Drejer et al., 1983a), 2) CGNs can be grown in the presence or 
absence o f astrocytes, unlike other primary neuronal cultures, and 3) they are an often 
used model in L-GLU-mediated excitotoxicity studies. The specific aims of this study 
can be summarized by the following questions:
1) What is the cellular distribution of GLAST, GLT-1, EAACl, and EAAT4 in 
primary cultures of rat cerebellar granule neurons?
2) Does the presence of glial cells alter the expression patterns of GLAST, GLT-1, 
EAACl, and EAAT4 in primary cultures of rat cerebellar granule neurons?
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These studies will improve the current understanding o f the distribution of the 
glutamate transporters in primary rat CGN cultures. This investigation will also provide 
further understanding o f the role that glial cells play in influencing EAAT expression 
patterns in neurons. Finally, this study will provide a needed data base for future studies 
on L-GLU transporters, particularly as related to regulation of expression, functional 
studies, developmental expression, and glutamate excitotoxicity. Future studies will aim 
to better understand the influence of astrocytes on neuronal EAAT expression and to 
utilize molecular methods to gain insight into how tremsporter expression patterns change 
with altered conditions, as can happen in pathological situations.
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MATERIALS AND METHODS
Tissue Culture
Primary cultures of rat cerebellar granule neurons (CGNs) and mixed CGN/glial 
cell cultures were prepared essentially as previously described (Schousboe et al., 1989). 
All animal procedures were in strict accordance with NTH Guide for the Care and Use of 
Laboratory Animals and were approved by the University of Montana AAALAC Animal 
Care Committee. Briefly, cerebellar tissue was aseptically removed from 7-day-old rat 
pups obtained from timed pregnant Sprague Dawley rats (Simonsen Laboratories, Gilroy, 
CA). The day o f birth was designated as postnatal day 0 (PO). Both culture types were 
prepared by a similar protocol, except that glial proliferation in CGN cultures was 
suppressed by adding cytosine arabinoside (20p.M) 24 hours after plating. This 
procedure kept the number of non-neuronal cells below 5% (Schousboe et al., 1989). 
Cerebellar tissue was dissected free from the meninges, transferred to a beaker containing 
10ml Krebs buffer (120mM NaCl, 5mM KCl, 1.2mM KH2 PO4 , 1.2mM MgS0 4 , 25mM 
NaHCOs, 13mM glucose, and 0.3% bovine serum albumin, pH 7.4, equilibrated with 
atmospheric air/CO:), and minced with sterile dissecting scissors. Minced tissue was 
transferred to a sterile 50ml tube, triturated with a Pasteur pipette, and centrifuged (3 min 
200 X g) at room temperature. Cells were dissociated by trypsinization (Type IX, Sigma, 
0.025% (w/v) in Krebs buffer, 15 min., 37° C). Immediately after the incubation, 20ml 
of Krebs buffer containing 0.004% (w/v) DNase I (Sigma) and 0.03% (w/v) soybean 
trypsin inhibitor (Type I-S, Sigma) was added to halt proteolytic activity. The mixture 
was centrifuged for 5 min at 200 x g; subsequently, the supernatant was removed and 
discarded. The pellet was resuspended in the presence of DNase I (0.004% (w/v) in
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Krebs buffer) and soybean trypsin inhibitor (0.003% (w/v) in Krebs buffer) followed by 
trituration. The cell suspension was left in the hood to allow sedimentation to occur. The 
supernatant, containing dissociated cells, was resuspended in 3ml of Eagle’s Minimum 
Essential Medium (EMEM, GibcoBrl). Media was supplemented to contain 24.5mM 
KCl, 30mM glucose, 7pM para-aminobenzoic acid, 100 mU/liter insulin, 10% fetal calf 
serum, (GibcoBrl), and 1 % antibiotic-antimycotic (GibcoBRl), then sterilized by 
filtration (.22|iM , Corning), and equilibrated with atmospheric air/CO 2  at 37° C 
(modified EMEM). The suspended cells were centrifuged for 5 min at 200 x g, the 
supernatant was discarded, and the pellet was resuspended in 10ml culture media 
(modified EMEM). Twenty-four hours prior to cell seeding, tissue culture plates (12- 
well, 3.8cm^, Costar) were prepared by inserting a round glass coverslips (18mm, VWR 
Scientific) in each well, coating the coverslips with poly-L-lysine (O.IM, Sigma), and 
allowing plates to sit in the tissue culture hood before rinsing £ind cell seeding. Cells were 
then seeded (1.0 x 10  ̂ cells/well) on the poly-L-lysine coated glass coverslips in 2 ml of 
culture media and allowed to grow for 10 days.
Culture M aintenance and Im m unocytochem istry Pretreatm ent
Twenty-four hours after seeding, 12-well plates were treated, where indicated, 
with 20pM  cytosine arabinoside (Sigma, St. Louis, MO) to halt proliferation of non­
neuronal cell types. Tissue culture media was changed every third day, and the cells 
were fixed at 10 days in vitro (10 DIV) with 4% paraformaldehyde in 0.1 M phosphate- 
buffered saline (pH 7.4) for 20 minutes. Fixative was aspirated, replaced with storage
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buffer (O.IM PBS, pH 7.4), and cells were stored at 4°C until processed. All 
immunostaining took place with in 5 days of fixation.
Antibodies
Four different subtype-specific antipeptide antibodies to glutamate transporters 
were used in this study. These rabbit polyclonal antibodies recognize distinct proteins for 
GLAST (543 amino acids; C-terminal), GLT-1 (573 amino acids; C-terminal), EAACl 
(523 amino acids; C-terminal), and EAAT4 (561 amino acids; C-terminal) (Alpha 
Diagnostics). Monoclonal antibodies to neurofilament (RMO270; NF; courtesy of Dr. 
Virginia Lee, Philadelphia, PA) and neuronal nuclei (NeuN, Chemicon, Temecula, CA) 
were used as markers for neuronal cytoskeleton and neuron specific nuclear protein, 
respectively. A monoclonal antibody against glial fibrillary acidic protein (GFAP, 
Chemicon) was used as a marker for astrocytes.
Single Label Im m unocytochem istry
Plates were removed from storage, rinsed twice with O.IM PBS, and blocked with 
either 5% normal horse sera (NHS, Vector Laboratories, Burlingame, CA) or 5% normal 
goat sera (NGS, Vector Laboratories) in O.IM PBS for 10 min. Cells were then 
permeabilized with 1% Triton X-100 in O.IM PBS for 10 min. A second 20-minute 
block with 5% NHS or 5% NGS, respectively, followed the permeabilization step. Cells 
were then immunostained using primary antibodies against one of the following: NF 
(1:100), NeuN (1:100), GFAP (1:100), GLAST (1:100), GLT-1 (1:100), EAACl (1:100), 
or EAAT4 (1:100). Both primary and secondary antibodies were diluted in O.IM Tris
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buffer solution containing 0.01% sodium Azide and 0.1% Bovine serum albumin (TAB). 
Primary antibody was added to the appropriate well, and incubated for 2 hours at 37°C. 
Primary antibodies were detected with the appropriate secondary antibody, FITC- 
conjugated horse anti-mouse (1:100; Vector Laboratories) or Cy3-conjugated goat anti­
rabbit (1:800; Jackson ImmunoResearch, West Grove, PA), for 1 hour at room 
temperature. Cells were rinsed twice with O.IM PBS, once with deionized water, 
coverslipped with Vectashield (Vector Laboratories), and stored at 4°C in the dark. For 
no-primary antibody controls, wells were treated in the same manner as experimental 
wells except control cells were incubated with secondary antibody alone.
Double Label Im m unocytochem istry
Plates were removed from storage, rinsed twice with O.IM PBS, then blocked 
with both 5% NHS and 5% NOS in O.IM PBS for 10 min. Cells were then permeabilized 
with 1% Triton X-100 in O.IM PBS for 10 min. A second 20-minute block with both 5% 
NHS and 5% NGS followed the permeabilization step. Cells were then immunostained 
using primary monoclonal antibody against either NF (1:100) or NeuN (1:100) or GFAP 
(1:100) diluted in TAB, and added to the appropriate well. Cells were incubated in 
primary antibody for 2 hours at 37°C. Primary monoclonal antibodies were detected with 
secondary antibody, FITC-conjugated horse anti-mouse (1:100; Vector Laboratories), for 
1 hour at room temperature. Cells were rinsed twice with O.IM PBS. Cells were then 
immunostained using primary polyclonal antibody GLAST (1:100), GLT-1 (1:100), 
EAACl (1:100), or EAAT4 (1:100) diluted in TAB, and added to the appropriate well. 
Cells were incubated in primary antibody for 2 hours at 37°C. Primary polyclonal
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antibody was detected with secondary antibody, Cy3-conjugated goat anti-rabbit (1:800; 
Jackson ImmunoResearch) for 1 hour at room temperature. Cells were rinsed twice with 
O.IM PBS, once with deionized water, coverslipped with Vectashield, and stored at 4°C 
in the dark. For no-primary antibody controls, wells were treated the same way as 
experimental wells except control cells were incubated with both secondary antibodies 
alone.
Im m unocytochem ical Analysis
All observations are based on a minimum N = 5, where N is the number of 
different tissue culture preparations. Within each preparation, at least 2 different culture 
plates were immunostained for the same transporters. Additionally, staining was done in 
duplicate by staining adjacent wells within each plate.
Microscope slides were viewed with a Nikon E-800 fluorescent microscope at 
magnifications ranging from 4-40X. Representative photographs were taken using 
Kodak Color Chrome Elite slide film (ASA 200) in a Nikon FX-35A camera. Slides 
were scanned into a Macintosh G4 computer using a Nikon Coolscan 4000 slide scanner 
and Nikon Scan 3.1 image analysis software. Adobe Photoshop 5.5 image analysis 
software was used to merge images into double labels. Additionally, some microscope 
slides were viewed with a Bio-Rad Radiance 2000 MP laser scanning confocal 
microscope. Representative photographs were taken using a Bio-Rad radiance 2000 MP 
multi-photon imaging system and viewed on a Dell Power Edge 1300 computer using 
LaserSharp 2000 software.
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RESULTS
Cell Culture Description — Cell Type Determination
Cerebellar granule neuron (CGN) cultures and mixed CGN/glial cell cultures 
prepared from 7-day old rats were characterized by immunocytochemistry. 
Immuno reactivity for neuro filament (NF) and neuronal nuclei (NeuN) were used to 
identify neurons, while astrocytes were identified by immunoreactivity for glial fibrillary 
acidic protein (GFAP). Cerebellar granule neuron cultures contain small granule neurons 
(6-9 um) which typically grow into large aggregates containing numerous cell bodies 
(Fig. 2C, arrows) with neuronal processes extending from the clusters of cell bodies (Fig. 
2A, arrows) (Schousboe et al., 1989). Although, replication of non-neuronal cells was 
halted by the addition of cytosine arabinoside in these cultures, a small number of 
astrocytes can remain. These astrocytes were rarely observed, however Fig. 2E (arrows) 
shows an example of astrocytes present in CGN cultures. Mixed CGN/glial cell cultures, 
in which cytosine arabinoside was not added, contain many neurons, as well as astrocytes 
(Fig. 2F, arrows). Although many astrocytes are present in this culture type, the neurons 
still grow as characteristic clusters o f cell bodies (Fig. 2D, arrows) with numerous 
processes projecting outward (Fig, 2B, arrows). In both culture types, neuronal clusters, 
as well as astrocytes appeared to be viable and healthy (based on trypan blue exclusion; 
results not shown) with intact cell bodies and many long processes.
Cell Culture Description -  L-Glutamate Transporter Expression
To investigate whether the two culture types (CGN cultures and mixed 
CGN/glial) contain the glutamate transporters, GLAST, GLT-1, EAACl, and EAAT4,
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subtype specific antibodies are used to label the transporters. Both culture types contain 
various cells that are immunopositive for the glutamate transporters, GLAST, GLT-1, 
EAACl, and EAAT4.
Both CGN cultures and m ixed CGN/glial cell cultures are positively 
immunoreactive for GLAST. Punctate, intense, labeling of GLAST is observed on 
filaments in both culture types, presumably neuronal filaments as judged by morphology 
(Fig. 3A and 4A, arrows). Positive GLAST immunoreactivity in clusters of cell bodies is 
also observed in both culture types (Fig. 3A and 4A, arrows). Clusters of cell bodies 
seen in CGN cultures (Fig. 3A, arrows) and in mixed CGN/glial cell cultures (Fig. 4A, 
arrows) are moderately labeled for GLAST. These clusters of cells are characteristic of 
cerebellar granule neurons grown in culture, as described in previous studies (Schousboe 
et al., 1985; Schousboe et al., 1989). Additionally, the size of these cells is consistent 
with being granule neurons (Schousboe et al., 1985; Schousboe et al., 1989) as well as 
the staining pattern (positive NeuN and NF immunoreactivity).
Immunostaining patterns for GLT-1 differs slightly between CGN cultures and 
mixed CGN/glial cell cultures. Although, there are many neuronal filaments in both 
culture types, the number of GLT-1 positive filaments slightly increases in CGN cultures 
(Fig. 3B, arrows) compared to the mixed CGN/glial cell cultures (Fig. 4B, arrows). From 
the staining patterns, it was quite apparent that NF staining was similar between these 
two culture types. Thus, the changes in GLT-1 immunoreactivity between cultures may 
not be attributable to changes in the number of neurofîlaments, but rather to differences 
in GLT-1 immunoreactivity on these filaments. Moderate labeling of the clusters of cell 
bodies is similar in both culture systems (Fig. 3B and 4B, arrows).
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Intense labeling o f EAACl is observed in clusters of cell bodies in both CGN 
(Fig. 3C, arrows) and mixed CGN/glial cell cultures (Fig. 4C, arrows). From the 
staining, we could see that there was not a differential EAACl pattern of expression 
between these two culture types.
Immunostaining o f EAAT4 in both types o f cultures exhibit different 
morphological patterns than those observed for all other EAATs on filaments. While 
filaments that are immunostained for GLAST, GLT-1, and EAACl are linear and 
typically connected clusters of cells, the EAAT4 positive filaments display a stellate 
appearance and are morphologically similar to astrocytic filaments (Fig. 3D and 4D). In 
addition, the number of EAAT4 positive cells varies between the two culture types. In 
CGN cultures, EAAT4 is expressed on a limited number of cells (Fig. 3D), while in 
mixed CGN/glial cell cultures (Fig. 4D), EAAT4 is expressed on numerous cells, as is 
expected if these filaments are indeed astrocytic filaments. Immunoreactivity of EAAT4 
on clusters of cell bodies is observed within both culture types (Fig. 3D and 4D). These 
cells display characteristic clumping typical of CGNs grown in vitro. Localization of the 
L-GLU transporter subtypes in both CGN cultures and mixed CGN/glial cell cultures is 
summarized in Table 2.
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Table 2. Cellular Distribution of Glutamate Transporters In Cerebellar 
Cell Cultures
G L A S T G L T - 1 E A A C l E A A T 4
C G N
C u l t u r e s
Neurons
Astrocytes
-Few
Neurons Neurons Neurons
Astrocytes
-Few
M i x e d
C G N / g l i a l
C e l l
C u l t u r e s
Neurons
Astrocytes
-Many
Neurons Neurons Neurons
Astrocytes
-Many
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Fig. 2. Cerebellar granule neuron (CGN) cultures and mixed CGN/glial cell cultures are 
immunostained for neurofilament (NF), neuronal nuclei (NeuN), and glial fibrillary 
acidic protein (GFAP) (green) (10 DIV). A) CGN cultures immunostained for NF. B) 
Mixed CGN/glial cell cultures immunostained for NF. C) CGN cultures immuno stained 
for NeuN. D) Mixed CGN/glial cell cultures immunostained for NeuN. E) CGN 
cultures immunostained for GFAP. F) Mixed CGN/glial cell cultures immunostained for 
GFAP. Immuno staining demonstrates that both types of primary cell cultures contain 
neurons with numerous filaments extending from clusters o f cell bodies. Although 
GFAP positive astrocytes are not generally observed in CGN cultures. Fig. 2E is 
representative o f those astrocytes present in CGN cultures. Numerous astrocytic 
filaments are observed in the mixed CGN/glial cell cultures. Mag Bar=50 |Lim
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Fig. 3. Cerebellar granule neuron (CGN) cultures immunostained for the excitatory 
amino acid transporters (red), GLAST, GLT-1, EAACl, and EAAT4 (10 DIV).
A) CGN cultures immunostained for GLAST. B) CGN cultures immunostained for 
GLT-1. C) CGN cultures immunostained for EA ACl. D) CGN cultures 
immunostained for EAAT4. Immunostaining exhibits the presence of the four glutamate 
transporters in this culture system. While the four transporters are present, they clearly 
have distinct expression patterns within this primary cell culture type. GLAST is mainly 
expressed on straight filaments, GLT-1 is found in both filaments and clusters of cell 
bodies. EAACl is predominantly found on clusters of cell bodies, and EAAT4 localizes 
to fibers with a stellate morphology. Mag Bar=50 pm
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Fig. 4. M ixed cerebellar granule neuron/glial cell cultures (mixed CGN/glial) 
immunostained for the excitatory amino acid transporters (red), GLAST, GLT-1, 
EAACl, and EAAT4 (10 DIV). A) Mixed CGN/glial cell cultures immunostained for 
GLAST. B) Mixed CGN/glial cell cultures immunostained for GLT-1. C) Mixed 
CGN/glial cell cultures immunostained for EAACL D) Mixed CGN/glial cell cultures 
immunostained for EAAT4. While the four transporters are present, they have distinct 
patterns of expression within this primary cell culture type. GLAST is mainly expressed 
on filaments, with moderate expression on clusters of cell bodies. GLT-1 is found in 
both filaments and clusters o f cell bodies. EAACl is found on clusters of cell bodies 
with limited expression in filaments. EAAT4 localizes to numerous fibers with a stellate 
morphology. Mag Bar=50 pm
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Double Labeling o f CGN Cultures and M ixed CG N/G lial Cell Cultures
To confirm transporter location on distinct cell types, dual-label experiments were 
used to probe the cultures for cell type (neurons, NF or NeuN and astrocytes, GFAP) and 
transporter subtype (GLAST, GLT-1, EAACl, EAAT4) expression. Utilization of the 
neuronal markers, NF and NeuN, allow for further delineation of transporter localization 
on either neuronal processes or neuronal cell bodies.
Identification o f  GLAST Positive Cells
Double labeling CGN cultures and mixed CGN/glial cell cultures with GLAST 
(red) and either NF, NeuN, or GFAP, (green) demonstrate that GLAST is expressed by 
both neurons and astrocytes. Neuronal processes are positively immunoreactive for 
GLAST in both CGN cultures (Fig. 5A, arrows) and in mixed CGN/glial cell cultures 
(Fig. 5D, arrows). Neuronal cell bodies also express GLAST in both culture types (Fig. 
5B and 5E, arrows). In general, there are few astrocytes present in CGN cultures, yet 
weak expression of GLAST is seen on a few of the remaining astrocytic filaments (Fig. 
5C). While numerous astrocytic filaments appear to be GLAST positive in the mixed 
cultures (Fig. 5F).
Identification o f  GLT-1 Positive Cells
Double labeling CGN cultures and mixed CGN/glial cell cultures with GLT-1 
(red) and either NF, NeuN, or GFAP (green) demonstrates that GLT-1 is expressed by 
neurons, but not astrocytes. GLT-1 expression is evident on neuronal filaments in both 
cultures (Fig. 6A and 6D). Neuronal filaments that express GLT-1 are more numerous in
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the CGN cultures than in the mixed CGN/glial cell cultures (Fig, 6A and 6D) and again 
this is not attributable to fewer filaments present in the mixed CGN/glial cell cultures. 
Intense GLT-1 expression is exhibited on neuronal cell bodies in both culture types (Fig. 
6B and 6E). GLT-1 expression by astrocytes is not observed in either culture type (Fig. 
6C and 6F), although neuronal filaments expressing GLT-1 do lie in close proximity to 
astrocytic filaments.
Identification o f  EAACl Positive Cells
Double labeling cell cultures with EAACl (red) and either NF, NeuN, or GFAP 
(green) demonstrates that EAACl is only expressed in neurons. While little to no 
expression of EAACl is observed on the neuronal filaments in both culture types (Fig. 
7A and 7D), intense EAACl expression is evident on neuronal cell bodies (Fig. 7B and 
7E). EAACl does not co-localize with GFAP positive astrocytes in either culture type 
(Fig. 1C and 7F).
Identification ofEAAT4 Positive Cells
Double labeling CGN cultures and mixed CGN/glial cell cultures with EAAT4 
(red) and either NF, NeuN, or GFAP (green) demonstrates that EAAT4 is predominantly 
expressed in astrocytes, although some expression is observed in neurons. EAAT4 
expression is not present on neuronal filaments (Fig. 8A and 8D) but localizes to 
neuronal cell bodies (Fig. 8B and 8E). EAAT4 expression is mainly observed in 
astrocytes as shown by occasional co-localization with GFAP positive filaments in CGN
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cultures (Fig. 8C) and numerous GFAP positive astrocytes in mixed CGN/glial cell 
cultures (Fig. 8F).
Confocal laser scanning microscopy with a highly sensitive fluorescence signal 
amplification system was used to visualize the distribution o f L-GLU transporter 
immunoreactivity more clearly. This technique is used to confirm cell type specific, 
GLAST, GLT-1, EAACl and EAAT4 transporter localization. These results show that 
GLAST, GLT-1, EAACl and EAAT4 are expressed by granule neurons (Fig. 9). Neither 
GLT-1 (Fig. lOB) nor EAACl (Fig. IOC) display astrocytic expression, however, both 
GLAST (Fig. 10A) and EAAT4 (Fig. lOD) are localized to cerebellar astrocytes present 
in  b o th  CGN c u ltu re s  and m ixed  C G N /g lia l c e ll cu ltu re s .
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Fig. 5. Cerebellar granule neuron (CGN) cultures and mixed CGN/glial cell cultures are 
dual-labeled for the glutamate transporter, GLAST (red), and one o f the cell-type 
markers, neuronal markers, NeuN or NF, or astrocyte marker, GFAP (green) (10 DIV). 
A) CGN cultures immunostained for GLAST and NF. B) CGN cultures immunostained 
for GLAST and NeuN. C) CGN cultures immunostained for GLAST and GFAP. D) 
Mixed CGN/glial cultures immunostained for GLAST and NF. E) Mixed CGN/glial 
cultures immunostained for GLAST and NeuN. F) Mixed CGN/glial cultures 
immunostained for GLAST and GFAP. Staining indicates that GLAST expression 
patterns do not vary widely between these two culture types. In both cultures GLAST is 
localized to neurons, both on the neuronal filaments and on the clusters of cell bodies. 
GLAST is also found on astrocytes in both culture types. Mag Bar=50 |xm
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Fig. 6. Cerebellar granule neuron (CGN) cultures and mixed CGN/glial cell cultures 
double labeled for the glutamate transporter, GLT-1 (red), and one of the cell-type 
markers, neuronal markers, NeuN or NF, or astrocyte marker, GFAP (green) (10 DIV). 
A) CGN cultures immunostained for GLT-1 and NF. B) CGN cultures immuno stained 
for GLT-1 and NeuN. C) CGN cultures immunostained for GLT-1 and GFAP. D) 
Mixed CGN/glial cell cultures immunostained for GLT-1 and NF. E) Mixed CGN/glial 
cell cultures immunostained for GLT-1 and NeuN. F) Mixed CGN/glial cell cultures 
immunostained for GLT-1 and GFAP. Immunostaining shows that neurons do express 
GLT-1. Immunoreactivity on neuronal clusters is similar in both culture types; however, 
more neuronal filaments in the CGN cultures are labeled for GLT-1 than the neuronal 
filaments in mixed CGN/glial cell cultures. Astrocytes do not appear to express GLT-1 
in either culture type, although GFAP positive filaments are sometimes found in close 
proximity to GLT positive filaments. Mag Bar=50 |Lim
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Fig. 7. Cerebellar granule neuron (CGN) cultures and mixed CGN/glial cell cultures 
dual-labeled for the glutamate transporter, EAACl (red), and one o f the cell-type 
markers, neuronal markers, NeuN or NF, or astrocyte marker, GFAP (green) (10 DIV). 
A) CGN cultures immunostained for EAACl and NF. B) CGN cultures immunostained 
for EAACl and NeuN. C) CGN cultures immunostained for EAACl and GFAP. D) 
Mixed CGN/glial cell cultures immunostained for EAACl and NF. E) Mixed CGN/glial 
cell cultures immunostained for EAACl and NeuN. F) Mixed CGN/glial cell cultures 
immuno stained for EAACl and GFAP. Clusters of neuronal cell bodies are strongly 
immunopositive for EA A C l, while neuronal filaments only exhibit weak, if  any, 
expression of EAACl in both culture types. Co-localization of EAACl and GFAP is not 
observed, suggesting astrocytes in these culture types do not express EAACl. Mag 
Bar=50 |im
42
43
Fig. 8. Cerebellar granule neuron (CGN) cultures and mixed CGN/glial cell cultures are 
dual-labeled for the glutamate transporter, EAAT4 (red), and one of the cell-type 
markers, neuronal markers, NeuN or NF, or astrocyte marker, GFAP (green) (10 DIV).
A) CGN cultures immunostained for EAAT4 and NF. B) CGN cultures immunostained 
for EAAT4 and NeuN. C) CGN cultures immunostained for EAAT4 and GFAP. D) 
Mixed CGN/glial cell cultures immunostained for EAAT4 and NF. E) Mixed CGN/glial 
cell cultures immunostained for EAAT4 and NeuN. F) Mixed CGN/glial cell cultures 
immunostained for EAAT4 and GFAP. Neuronal filaments are not immunopositive for 
EAAT4, although clusters of neuronal cell bodies do moderately express EAAT4 in both 
culture systems. The few remaining astrocytes present in CGN cultures as well as the 
numerous astrocytes present in the mixed CGN/glial cell cultures are intensely 
immunopositive for EAAT4. Mag Bar=50 jim
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Fig. 9. Confocal images of cerebellar granule neuron (CGN) cultures double labeled 
for NeuN (green) and one of the glutamate transporters (red), GLAST, or GLT-1, or 
E A AC 1, or EAAT4 (10 DIV). A) CGN cultures immunostained for NeuN and GLAST.
B) CGN cultures immunostained for NeuN and GLT-1. C) CGN cultures 
immunostained for NeuN and E A AC 1. D) CGN cultures immunostained for NeuN and 
EAAT4. The four glutamate transporters, GLAST, GLT-1, E A AC 1, and EAAT4 do co- 
localize with NeuN, confirming that granule neurons express these transporters. Mag 
Bar=50 pm
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Fig. 10. Laser scanning confocal microscopy images o f cerebellar granule neuron 
(CGN) cultures double labeled for GFAP (green) and one of the glutamate transporters, 
GLAST, or GLT-1, or EA A C l, or EAAT4 (red) (10 DIV). A) CGN cultures 
immunostained for GFAP and GLAST. B) CGN cultures immunostained for GFAP and 
GLT-1. C) CGN cultures immunostained for GFAP and EAACL D) CGN cultures 
immunostained for GFAP and EAAT4. GLAST and EAAT4 demonstrate co-localization 
with GFAP, while no co-localization was observed with GLT-1 or EAACl and GFAP. 
Mag Bar=50 pm
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DISCUSSION
The existence of multiple excitatory amino acid transporter (EAAT) subtypes 
raises the possibility that EAATs play a variety of roles in the central nervous system 
(CNS). Studying the expression patterns of L-GLU transporter subtypes is an important 
approach for elucidating the potential for distinct EAAT contributions to excitatory 
signaling, metabolic regulation, or excitotoxic protection. Major advances in the field 
came with the cloning o f Na^-dependent excitatory amino acid transporter subtypes, 
GLAST (Storck et ah, 1992), GLT-1 (Pines et al., 1992), EAACl (Kanai, 1992), and 
EAAT4 (Fairman, 1995). Molecular probes were then produced which allowed for 
identification of the tissue distribution of these transporter subtypes. The initial studies 
examining the localization of EAATs involved mRNA studies utilizing adult mammalian 
tissue preparations. More recently, localization studies using antibodies generated 
against the various transporter subtypes determined localization via immunocytochemical 
and immunohistochemical methods, again in mature mammalian CNS systems. These in 
vitro and in vivo studies provide insight into the multiple tasks that the transporters 
execute in their regulation of extracellular L-GLU concentrations. Additionally, these 
studies set the accepted standards for cellular localization: GLAST and GLT-1 being 
described as ‘glial glutamate transporters’, EAACl as the ‘neuronal glutamate 
transporter’, and EAAT4 as being restricted to cerebellar Purkinje neurons. However, 
more recent results have revealed that these presumed transporter distribution patterns are 
not absolute. Studies have continued to utilize subtype specific antibodies to further 
elucidate cellular and subcellular localization of the EAATs in a variety of in vitro and in 
vivo preparations throughout each of the stages of development.
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Determining transporter localization and subtype specific roles in excitatory 
transmission and excitotoxicity provides the potential for the development of agents with 
which to regulate transporter-mediated processes. Numerous investigations focusing on 
transmission, transport, and L-GLU mediated excitotoxicity have utilized cerebellar 
granule neuron cultures as a model experimental system. These cultures represent a 
glutamatergic neuronal system and provide a highly controlled environment for 
experimentation. Additionally, these cultures are useful because neurons and glia are 
easily distinguished at the microscopic level and because CGNs can be cultured in the 
absence of glia. The present study characterizes the cellular localization of the Na^- 
dependent, high affinity L-GLU transporters, GLAST, GLT-1, EAACl, and EAAT4, in 
primary cerebellar granule neurons (CGNs) and mixed CGN/glial cell cultures prepared 
from 7-day-old rat cerebella. Our results demonstrate that GLAST, GLT-1, EAACl, and 
EAAT4 are found in granule neurons and that GLAST and EAAT4 are also present on 
astrocytes provides important data towards defining the functional importance of these 
transporters.
C ellular Distribution o f EAATs
In the present in vitro study, GLAST predominantly localizes to granule neurons 
in both culture types. Additionally, GLAST localizes to some, but not all, GFAP positive 
astrocytes. Our demonstration o f GLAST localization to neurons, contrasts with initial 
reports demonstrating that GLAST is restricted to mature glial cells, particularly 
Bergmann glia in the cerebellar cortex (Storck et al., 1992; Schmitt et al., 1997). More 
recent studies, however, demonstrate that this presumed astroglial transporter is also
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expressed in neuronal cells. These studies report that GLAST is localized to neurons in 
mature cerebellar tissue slices (Rothstein et al., 1994), as well as in human CNS tissue 
(Arriza et al., 1994). Similar findings have also been reported for cultures of rat 
hippocampal neurons (Mennerick, 1998). Therefore, our finding that both cerebellar 
granule neurons and astrocytes express GLAST is consistent with the more recent 
conclusions that GLAST may function as either a neuronal or astrocytic L-GLU 
transporter.
Similarly, our results provide evidence that neurons also express the L-GLU 
transporter, GLT-1. We demonstrate GLT-1 expression is localized to cerebellar granule 
neurons in CGN cultures and mixed CGN/glial cell cultures. More specifically, we show 
that the majority o f staining is present on neuronal processes and cell bodies. Again, our 
findings contrast with initial cloning experiments that showed GLT-1 mRNA and protein 
were largely restricted to astrocytes in adult rat preparations (Pines et al., 1992; Rondo et 
al., 1995; Danbolt et al., 1998). However, in addition to the present study, more recent 
reports have also demonstrated that GLT-1 is expressed by neurons (Mennerick, 1998). 
GLT-1 expression has been described in glial cell-depleted cultures of cortical neurons 
and in certain neurons of the retina (Wang et al., 1994). Additionally, GLT-1 mRNA has 
been detected in neurons from the hippocampus (Torp et al., 1994) and from several other 
regions (Schmitt et al., 1997). Thus, our results provided further evidence that CNS 
expression o f the L-GLU transporter GLT-1 is not restricted to astrocytes as originally 
hypothesized.
Our results demonstrate that EAACl is localized to granule neurons, grown both 
in the presence and absence of astrocytes, and that EAACl is not localized to GFAP
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positive astrocytes. These findings are in agreement with initial cloning studies that 
reported observing only neuronal EAACl localization (Kanai, 1992; Vandenberg, 1998), 
not only in rat (Velaz-Faircloth et al., 1996), but also in humans (Arriza et al., 1994). 
Our immunocytochemical data are consistent with the specific expression of EAAC1 in 
neurons, since double labeling using an antibody against GFAP verified that astrocytes, at 
least in 10-day-old cultures, were not contributing to the observed transporter 
immunoreacti vity.
We found EAAT4 protein localized predominantly to astrocytes in both CGN 
cultures and mixed CGN/glial cell cultures. In some instances however, neuronal cell 
bodies, but not neuronal processes, exhibit EAAT4 expression. Initial studies 
demonstrated that EAAT4 localizes to cerebellum, specifically Purkinje neurons 
(Fairman, 1995). However, our results suggest that EAAT4 is not strictly localized to 
Purkinje neurons, but is also present on granule neurons in addition to cerebellar 
astrocytes. To date, this is the first report demonstrating that EAAT4 can be expressed 
by astrocytes. It must be noted, however, that commercial antibodies have only been 
recently made available against this transporter, so future studies may find additional 
examples which show that astrocytes in other brain regions do in fact express EAAT4.
As demonstrated by this project, as well as by many others, there has been 
considerable variation among studies aimed at determining the cellular distribution of the 
various EAAT subtypes. There are, however, significant variables that may account for 
differences in the results from these studies. Variations in transporter expression patterns 
during development have been reported, as well as differences related to in vitro culturing 
conditions (Gegelashvili and Schousboe, 1997a). Developmental expression patterns of
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L-GLU transporter subtypes have been the subject of several reports (Sutherland et al., 
1996; Bar-Peled et al., 1997; Yamada et al., 1997). L-Glutamate is thought to participate 
in several processes that occur during neuronal development, such as cell migration, cell 
differentiation, and neuronal and astroglial proliferation (Bar-Peled et al., 1997). In this 
respect, L-GLU transporters may play a role in the developmental processes by 
regulating L-GLU levels. Currently, it is known that transporter expression patterns 
change throughout CNS maturation. GLAST protein and mRNA are found at low levels 
in the postnatal cerebellum and increase to reach adult expression levels near postnatal 
day 26 (Furuta et al., 1997). Additional studies suggested that GLAST expression may be 
both neuronal and glial in early development, switching to a strict astroglial expression 
pattern in the mature brain (Bar-Peled et al., 1997). Our investigation provides further 
evidence demonstrating GLAST expression in the cerebellum at an early developmental 
stage in both neurons and astrocytes. Like GLAST, GLT-1 levels also increase during 
development. GLT-1 levels are virtually undetectable at birth, gradually increasing in the 
first month of development, reaching peak levels near postnatal day 26 (Kondo et al., 
1995; Furuta et al., 1997; Swanson et al., 1997). This may explain why we did not see 
GLT-1 expression in astrocytes in our experiments. Interestingly, neuronal EAACl 
expression decreases throughout development. EAACl expression is highest early in 
development with peak levels observed near postnatal day 5 (Rothstein et al., 1994; 
Yamada et al., 1996). We demonstrate strong expression of EAACl by granule neurons 
in our cultures, consistent with previously described developmental expression patterns. 
The presence o f EAAT4 mRNA in neurons has been shown to increase dramatically 
during maturation, especially during the period associated with synaptogenesis in rat
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(Furuta et al., 1997). However, EAAT4 protein expression in Purkinje cells may occur 
much later in development, being detectable primarily in the mature cerebellum (Yamada 
et al., 1996). Our results show that cell types, other than just Purkinje neurons may 
express EAAT4 especially early in development.
Several hypotheses have been developed regarding alterations in transporter 
expression patterns observed during development. Potentially, cells may have an 
uncommitted L-GLU transporter phenotype, with cell-type specificity for L-GLU 
transporter phenotype occurring with maturity (Yamada et al., 1996). Another possibility 
is that neurons may express a greater diversity o f transporter subtypes during 
development (Yamada et al., 1996). Such a possibility is consistent with the hypothesis 
that L-GLU transport by neurons predominates over astroglial transport of L-GLU during 
development (Furuta et al., 1997). While these hypotheses have yet to be proven, our 
results demonstrating neuronal expression of GLAST, GLT-1, EAACl, and EAAT4 
appear consistent. Additionally, our results are consistent with the idea that a different 
group of transporters may be responsible for the clearance of extracellular L-GLU early 
in development than in the mature brain (Bar-Peled et al., 1997). The diversity of EAAT 
subtypes observed during the developmental process suggests multi-functional roles for 
L-GLU transporters. Before synapses have completely formed, L-GLU transporters may 
play additional roles beyond maintaining low concentrations of L-GLU in the 
extracellular space.
Several reports have demonstrated that in vitro culture systems exhibit patterns of 
L-GLU transporter expression which differ from those observed in vivo, suggesting that 
culture conditions may influence L-GLU transporter activity and expression [Kondo,
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1995 #27; Swanson, 1997 #56]. Interestingly, our results did not show a recognizable 
change in neuronal transporter expression when the cells were grown in the presence or 
absence of astrocytes. Others have shown changes in expression, particularly with GLT- 
1, although, these studies were not performed in cerebellar granule neuron cultures. 
Specifically, studies have demonstrated that GLT-1 expression is severely downregulated 
in cultured cortical astrocytes when compared to in vivo findings (Gegelashvili et al., 
1996; Gegelashvili and Schousboe, 1998). Further evidence suggesting changes in 
transporter subtype expression due to growth conditions is provided by studies that show 
transporter sensitivity to uptake inhibitors differ when compared between in vitro and in 
vivo experiments (Gegelashvili and Schousboe, 1998). Molecular expression and activity 
of L-GLU transporters are also amenable to differential regulation by a number of 
bioactive substances (Gegelashvili et al., 1996). For example, a deficiency of certain 
metabolites in the culturing media may be involved in regulation o f transporter 
expression (Gegelashvili et al., 1996). Interestingly, it has been reported that certain 
neuronal growth factors (e.g., nerve growth factor, fibroblast growth factor, brain-derived 
neurotrophic factor) may be essential for the expression of GLT-1 in astrocytes (Drejer 
et al., 1983b; Gegelashvili et al., 1997; Swanson et al., 1997; Figiel and Engele, 2000). 
Therefore, L-GLU transporter expression patterns observed in this investigation, may be 
a reflection of the ex vivo environment of the cultured cells. Specifically, the expression 
of GLAST by cerebellar granule neurons, the lack of astrocytic GLT-1 expression, and 
expression o f EAAT4 by both cerebellar granule neurons and astrocytes, may be 
attributable to the conditions in which these cells were grown.
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Functional Significance
As stated before, it is currently thought that L-GLU transporters may play a role 
in transmitter recycling, signal termination, and excitotoxic protection. In this respect, 
determining the cellular and subcellular distribution of the transporters should provide 
valuable insight into subtype specific roles in these processes. For example, it can be 
presumed that transporters must be localized to the synaptic cleft region to participate in 
signal termination. In contrast, localization to areas outside of the synaptic cleft may be 
indicative o f roles other than signal termination. Indeed, cell body or axonal localization 
may indicate that the transporters are playing a metabolic role in these cells, such as 
protein synthesis or precursor acquisition for neuro transmitter synthesis. Based on 
studies performed to date, neuronal expression of EAATs is postulated to function in 
excitotoxic protection and in metabolism. Unfortunately, in this investigation the image 
resolution could not provide information as to the subcellular localization of the 
transporters. Therefore, we could not determine whether the various transporters 
demonstrated distinct subcellular patterns of expression, showing either cell body 
localization or synaptic cleft localization.
GLAST localization to the synaptic cleft would be consistent with the presumed 
role in clearance o f neurotransmitter for signal termination, however, GLAST 
localization to areas outside of the synaptic cleft would suggest that GLAST plays a more 
significant role in precursor uptake. Kinetic studies have shown that GLAST has a 
higher Km (77 fxM) for L-GLU than both GLT-1 (2 |im ) and EAACl (17 jim) 
(Gegelashvili and Schousboe, 1997b). This information supports the idea that GLAST
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functions as a lower affinity reserve uptake system backing up the higher affinity systems 
in CNS tissue (Kanai et al., 1994a). L-Glutamate uptake through GLAST has been 
suggested to play a role in metabolism due the localization of GLAST to peripheral tissue 
as well as CNS tissue. Therefore, in addition to terminating the action of synaptically 
released L-GLU at central synapses, the localization of GLAST to glutamatergic neurons 
may suggest additional functions in the regulation of other aspects of L-GLU signaling.
It is generally well accepted that L-GLU transporters play a physiological role in 
astrocytes. While the predominant astrocytic L-GLU transporter GLT-1 plays a major 
role in the glutamate-glutamine shuttle, our findings demonstrating astrocytic GLAST 
localization suggests that this EAAT may also play a role in the glutamate-glutamine 
shuttle. Astrocytic GLAST may allow for L-GLU uptake leading to the subsequent 
metabolic conversion to glutamine by the action of glutamine synthetase, an enzyme that 
is highly concentrated in astrocytes. Neighboring neurons are then able to use the 
released glutamine as a precursor for L-GLU synthesis. Thus, astrocytic expression of 
GLAST may provide additional glutamate-transporting capacity (Kanai et al., 1994b) that 
may serve to protect neurons from excitotoxicity.
Gegelashvili et al., 1997 reported that the ‘glial L-GLU transporter’ GLT-1, has 
the highest affinity for L-GLU when compared to other EAATs (Gegelashvili and 
Schousboe, 1997b). It is also known that glial cells are responsible for clearing the 
majority o f synaptically released L-GLU. Although, L-GLU uptake sites have also been 
shown to exist on neurons (Gegelashvili and Schousboe, 1998). Interestingly, Mennerick 
et al. (1998) showed that neuronal GLT-1 participates in the clearance of synaptically 
released L-GLU (Mennerick, 1998). Therefore, cerebellar granule neuron expression of
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GLT-1 may represent an alternate mechanism for clearance of synaptically released L- 
GLU in the cerebellum. A subcellular distribution pattern for GLT-1 is necessary to 
establish whether GLT-1 plays a role in excitotoxic protection or signal termination in 
granule neuron cultures. Our demonstration of GLT-1 localization to neuronal cell 
bodies in CGN cultures may be indicative of an alternate role in neurotransmission.
Neuronal expression of EAACl has previously been documented (Fairman, 
1995). To date, glial expression of EAACl has only been shown in tumor cells, 
specifically rat C6 glioma cell lines and several human tumors of glial origin (Kanai, 
1992; Kanai et al., 1994a; Rothstein et al., 1994; Vandenberg, 1998), and not in primary 
cultures or tissue sections. Neuronal expression of this high affinity L-GLU transporter 
(Km 17|im) suggests that neuronal uptake of L-GLU plays an important role in excitatory 
amino acid neurotransmission. We demonstrate EAACl localization predominantly to 
neuronal cell bodies and not neuronal filaments or astrocytes. This finding suggests that 
EAACl probably does not play a major role in signal termination, but may rather 
function in a capacity more closely linked to metabolism and excitotoxic protection in 
these culture systems. However, not all of the information known regarding EAACl is 
consistent with this role for EAACl in granule neurons. EAACl mRNA is found in 
GABAergic neurons isolated from rat preparations (Rothstein et al., 1994; Gegelashvili 
and Schousboe, 1998). These data raise the possibility that EAACl plays a role 
transporting the necessary precursors for G ABA synthesis, instead of or in addition to, a 
role in L-GLU clearance. Localization of EAACl to peripheral tissue as well as CNS 
tissue is consistent with this idea.
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EAAT4 expression on cerebellar granule neurons as well as astrocytes within our 
culture system provides little insight as to the physiological role of EAAT4. EAAT4 
localization on granule neuron cell bodies suggests this transporter does not play a 
prom inent role in signal termination. However, our demonstration o f EAAT4 
localization on glial cells lying in close proximity to clustered neurons suggests astrocytic 
EAAT4 may play a role in signal termination, excitotoxic protection, and/or the 
glutamate-glutamine cycle. A more complete subcellular distribution of this transporter 
in both neurons and glia is necessary to elucidate the functional significance of this 
transporter and develop specific therapies for the treatment of various disease states.
L-G lutam ate Transporters as Therapeutic Targets
Selective pharmacological agents are required to further elucidate the specific 
roles of L-GLU transporters in the pathogenesis of neurological disorders. Because L- 
GLU transporters are widely distributed throughout the CNS, they may prove to be 
valuable as potential molecular targets for both neuropsychiatrie and neurodegenerative 
disorders (Lipton and Rosenberg, 1994; Dunlop et al., 1999). Determining subtype 
specific pharmacology through the use o f transport inhibitors may lead to a better 
understanding of the respective roles that transporters play in normal and pathological 
states (Rothstein et al., 1996; Bergles and Jahr, 1997). Targeting these transporters for 
the development o f drugs was initially considered to be counterintuitive because total 
inhibition of L-GLU transport was assumed to have neurotoxic effects. However, it is 
now becoming apparent that not all L-GLU transporters contribute equally to signal 
termination, transmitter recycling, and excitotoxicity. Therefore, partial inhibition of a
59
subset o f L-GLU transporters may be therapeutically useful in the treatment of 
neurological disorders. For example, partial inhibition of L-GLU transport may 
beneficial in schizophrenia, a condition in which reduced glutamatergic output is thought 
to contribute to pathogenesis (Robinson, 1998). In the case of epilepsy, excessive L- 
GLU is released and a strategy to enhance the activity of L-GLU transporters would be 
desirable (Olney et al., 1986; Akbar et al., 1998).
Developing L-GLU transport inhibitors may also be effective in the treatment of 
pathogenic conditions where reverse transport is implicated. Reverse transport occurs 
when L-GLU is released by the cell through the reversal of L-GLU uptake and the 
movement of L-GLU down its concentration gradient into the extracellular space leading 
to excitotoxicity (Billups et al., 1998). Reverse transport may occur in cases of ischemia 
where lack of oxygen and depleted energy supply cause transmembrane ion gradients to 
run down (Billups et al., 1998). Therefore, compounds that selectively block reverse 
transport may be useful in limiting reverse L-GLU transport associated with ischemia.
Cerebellar granule neuron cultures are widely utilized in studies of transporter 
function that rely on pharmacological inhibitors (Campbell and Shank, 1978; Balcar et 
al., 1987; Griffins et al., 1989; Lysko et al., 1994). Dihydrokainate (DHK) has been 
previously identified as a selective inhibitor of GLT-1 (Monaghan et al., 1989; Bridges et 
al., 1999; Koch et al., 1999; Brauner-Osborne et al., 2000). Results obtained from our 
investigation suggest that GLT-1 localizes to neurons in CGN cultures and mixed 
CGN/glial cell cultures unlike some other experimental systems where GLT-1 is found 
on astrocytes and not neurons. When observing transport inhibition by DHK in other 
culture systems, it may have been assumed that DHK was blocking uptake in to glia not
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neurons. Therefore, results obtained in our investigation may change the interpretation of 
previous transport inhibitor studies performed in CGN culture system. Additionally, our 
results demonstrating cell type transporter expression in CGN cultures will be essential to 
properly interpret future results obtained from pharmacological transport inhibitor studies 
using this in vitro preparation.
Future Studies
Because CGN cultures are a widely utilized system for studying glutamatergic 
neurotransmission, it is essential to precisely define specific cell-type transporter 
expression patterns to proceed with future studies utilizing this system. CGN culture 
systems may provide valuable insight into the regulation of transporter expression (e.g., 
growth factor regulation and developmental regulation) and the design of 
pharmacological agents with which to regulate transporter function (e.g., pharmaceutical 
inhibitors and methods to increase transporter function such as gene therapy. Thus, our 
description of transporter expression patterns in this culture system is essential to gain 
further understanding into the specific roles that L-GLU transporters play in normal 
physiology and pathology.
An essential step in determining functional roles of the transporter subtypes is to 
further define the subcellular distribution patterns o f these transporters. 
Immunocytochemical methods represent one potential method for determining 
subcellular distribution. Investigations could utilize antibodies against synaptic proteins 
(proteins that specifically localize to the synaptic areas of neurons) to see if they co- 
localize with L-GLU transporter subtypes. It is important to know which transporters
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have synaptic localization as this knowledge may allow for speculations regarding the 
specific roles that transporters play in glutamatergic neurotransmission.
Future studies are also needed to develop therapies targeted toward specific L- 
GLU transporter subtypes. Researchers have previously explored L-GLU receptor 
antagonists, metabolic inhibitors, and release inhibitors to decrease the toxic effects to 
neurons by L-GLU with varying degrees o f success. The task has proven to be very 
difficult due to differences in function and distribution that each transporter exhibits 
depending on the nature of the uptake systems (brain slice, cell cultures, synaptosomes, 
and other membrane preparations). Because L-GLU transporters represent a potential 
regulatory mechanism to control the balance between physiological signaling and 
excitotoxic pathology, modulation of L-GLU transporter expression may prove to be a 
strong target for novel drug discovery (Takahashi et al., 1997; During and Asthenden, 
1998; Dunlop et al., 1999).
Future studies using molecular methods to transfect the various EAATs into 
neurons or glia in a cell culture environment, as well as animal models of disease, may 
have therapeutic value in diseases like Amyotrophic Lateral Sclerosis (ALS) and epilepsy 
(Hurko and Walsh, 2000). Evidence indicates that chronic suppression of L-GLU 
transport in ALS may be a significant factor in the pathophysiology of this disease 
(Rothstein et al., 1992). Lin et. al showed that the presence o f aberrantly spliced 
transcripts from the GLT-1 gene are responsible for the reduction of functional GLT-1 
protein and activity observed in ALS brains (Lin, 1998). Therefore, gene therapy aimed 
at enhancing expression of the GLT-1 transporter in ALS patients is a therapeutic goal.
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In order to utilize CGN cultures to design future gene therapy experiments, it is 
essential to understand which transporter subtypes should be expressed and which cell 
type to attempt to increase expression. For example, if  the goal were to increase 
expression of GLT-1 into neurons, it would be valuable to determine whether or not 
neurons can express GLT-1 at some time in their developmental process. Data obtained 
from our investigation shows that cerebellar granule neurons do have the capacity to 
express GLT-1. Thus, transfecting neurons with GLT-1 may be a reasonable strategy for 
gene therapy.
With cell-type specific expression patterns of the L-GLU transporters in CGN 
cultures now known, results obtained from future studies utilizing these cultures may be 
more precisely interpreted. Utilizing this in vitro culture system may prove to be a 
valuable tool gaining a more precise understanding of transporter function. Additionally, 
this in vitro culture system may be a useful tool for development of specific therapies 
targeted towards the L-GLU transporters.
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